Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020

TLDR

Sexually transmitted infections caused by Neisseria gonorrhoeae have risen 63 % since 2014, causing serious sequelae and facilitating HIV transmission, and treatment is complicated by rising antimicrobial resistance, prompting reevaluation of CDC recommendations. The report updates CDC guidelines by recommending a single 500 mg intramuscular dose of ceftriaxone for uncomplicated urogenital, anorectal, and pharyngeal gonorrhea. Concurrent doxycycline 100 mg orally twice daily for 7 days is advised when chlamydia is not ruled out. Ongoing surveillance of ceftriaxone resistance and reporting of treatment failures is essential to maintain regimen efficacy.

Abstract

Sexually transmitted infections (STIs) caused by the bacteria Neisseria gonorrhoeae (gonococcal infections) have increased 63% since 2014 and are a cause of sequelae including pelvic inflammatory disease, ectopic pregnancy, and infertility and can facilitate transmission of human immunodeficiency virus (HIV) (1,2). Effective treatment can prevent complications and transmission, but N. gonorrhoeae's ability to acquire antimicrobial resistance influences treatment recommendations and complicates control (3). In 2010, CDC recommended a single 250 mg intramuscular (IM) dose of ceftriaxone and a single 1 g oral dose of azithromycin for treatment of uncomplicated gonococcal infections of the cervix, urethra, and rectum as a strategy for preventing ceftriaxone resistance and treating possible coinfection with Chlamydia trachomatis (4). Increasing concern for antimicrobial stewardship and the potential impact of dual therapy on commensal organisms and concurrent pathogens (3), in conjunction with the continued low incidence of ceftriaxone resistance and the increased incidence of azithromycin resistance, has led to reevaluation of this recommendation. This report, which updates previous guidelines (5), recommends a single 500 mg IM dose of ceftriaxone for treatment of uncomplicated urogenital, anorectal, and pharyngeal gonorrhea. If chlamydial infection has not been excluded, concurrent treatment with doxycycline (100 mg orally twice a day for 7 days) is recommended. Continuing to monitor for emergence of ceftriaxone resistance through surveillance and health care providers' reporting of treatment failures is essential to ensuring continued efficacy of recommended regimens.